The past six months haven’t been great for Sarepta Therapeutics. It just made a new 52-week low of $52, and shareholders have ...

Sarepta and Roche announced a 16-year-old US patient dosed with the gene therapy died of acute liver failure in March 2025.

Key Takeaways Some studies of Sarepta Therapeutics' muscular dystrophy drug, Elevidys, have been halted by European ...

A few weeks after Sarepta Therapeutics confirmed a patient died after receiving its drug Elevidys, research published April 3 ...

In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...

Oppenheimer analyst Andreas Argyrides lowered the firm’s price target on Sarepta (SRPT) to $184 from $215 and keeps an Outperform rating on the ...

President Trump yesterday announced a baseline tariff of 10% on all imported products and higher rates on certain countries ...

Scotiabank analyst Louise Chen maintained a Hold rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

One day after the European Medicines Agency requested that three clinical trials of Elevidys be placed on hold after the ...

Needham analyst Gil Blum lowered the firm’s price target on Sarepta (SRPT) to $183 from $202 and keeps a Buy rating on the ...

With a volume of 1,234,594, the price of SRPT is down -6.84% at $58.2. RSI indicators hint that the underlying stock may be ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...